| A Study to Evaluate the Safety and Efficacy of VGB-R04 in Adult Hemophilia B Patients (NCT05441553) | Shanghai Vitalgen BioPharma Co., Ltd. | 2022-07-01 |
| Validation and Reliability of the CHO-KLAT in Turkish (NCT05439642) | Yuzuncu Yil University | 2022-06-01 |
| Study of Surgical Practices in Patients With Haemophilia A or B Treated With an Extended Half-life Recombinant Factor VIII-Fc or IX-Fc (ELOCTA®, ALPROLIX®) (NCT06158334) | Hospices Civils de Lyon | 2022-06-01 |
| Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With Inhibitor (NCT05487976) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2022-04-28 |
| A Study to Evaluate the Safety and Efficacy of ZS801 in Adult Hemophilia B Patients (NCT05641610) | Institute of Hematology & Blood Diseases Hospital, China | 2022-02-16 |
| Needs Assessment of Knowledge, Beliefs, and Attitudes of Patients With Hemophilia B About Gene Therapy (NCT05044845) | St. Jude Children's Research Hospital | 2022-01-18 |
| Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy Drug (NCT05203679) | Shanghai Xinzhi BioMed Co., Ltd. | 2021-12-30 |
| Safety and Tolerability of VGB-R04 in Patients With Haemophilia B (NCT05152732) | Institute of Hematology & Blood Diseases Hospital, China | 2021-12-28 |
| Phase 1/2 Dose Confirmation Study of FLT180a in Hemophilia B (NCT05164471) | Spur Therapeutics | 2021-12-06 |
| Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors (NCT05145127) | Pfizer | 2021-11-17 |
| Pre-clinical Models for Mesenchymal Stem Cell Therapy in Hemophilic Arthropathy (NCT05187936) | University Hospital, Montpellier | 2021-10-01 |
| Vitamin K Antagonist Versus Direct Oral Anticoagulant Treatments in Hemophilia (NCT05804734) | Groupe Maladies hémorragiques de Bretagne | 2021-06-01 |
| Psychometric Validation of the Hemophilia Functional Ability Scoring Tool (Hemo-FAST) (NCT04731701) | Swedish Orphan Biovitrum | 2021-05-05 |
| Study of AAV5-hFIX in Severe or Moderately Severe Haemophilia B (NCT05360706) | CSL Behring | 2021-03-18 |
| Medication Adherence and Non-adherence in Adults With Rare Disease (NCT04541875) | Xperiome | 2021-01-01 |
| National Longitudinal Cohort of Hematological Diseases (NCT04645199) | Institute of Hematology & Blood Diseases Hospital, China | 2020-12-01 |
| Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX (NCT04628871) | Sangamo Therapeutics | 2020-11-03 |
| A Phase 1/2 Study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B Subjects (NCT04394286) | Baxalta now part of Shire | 2020-05-13 |
| Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B (NCT03938792) | Pfizer | 2020-03-09 |
| AAV Gene Therapy Screening/Observational Protocol (ECLIPSE) (NCT04272554) | Spur Therapeutics | 2020-02-14 |
| Gaining Insight Into the Complexity of Pain in Patients With Haemophilia (NCT05606640) | Universiteit Antwerpen | 2020-02-13 |
| Nonacog Alfa Prophylaxis And Treatment Of Bleeding Episodes In Previously Treated Patients With Hemophilia B (NCT04286412) | Pfizer | 2020-02-10 |
| Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B (NCT03855280) | Medexus Pharma, Inc. | 2020-01-16 |
| Gene Therapy for Chinese Hemophilia B (NCT04135300) | Institute of Hematology & Blood Diseases Hospital, China | 2019-10-16 |
| Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia (NCT04072237) | Catalyst Biosciences | 2019-09-24 |
| An International Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B (NCT03901755) | Swedish Orphan Biovitrum | 2019-09-12 |
| The Safety and Tolerability of SerpinPC in Healthy Men and in Men with Severe Blood Disorders (haemophilia a and B) (NCT04073498) | ApcinteX Ltd | 2019-08-14 |
| A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B (NCT03861273) | Pfizer | 2019-07-29 |
| Personalized Medicine for Canadians With Hemophilia (NCT03615053) | McMaster University | 2019-07-24 |
| Study of Next-Generation Recombinant Factor IX Variant in Adult Subjects With Hemophilia B (NCT03995784) | Catalyst Biosciences | 2019-06-18 |
| Mutation p.Ile112Thr : Discrepancy Between Factor IX Level and Bleeding Phenotype (NCT03946384) | Centre Hospitalier Universitaire Dijon | 2019-06-01 |
| RIXUBIS PMS India (RIXUBIS PMS) (NCT03565237) | Baxalta now part of Shire | 2018-12-07 |
| Early Check: Expanded Screening in Newborns (NCT03655223) | RTI International | 2018-10-15 |
| ATHN 8: Previously Untreated Patients (PUPs) Matter Study (NCT03818529) | American Thrombosis and Hemostasis Network | 2018-10-03 |
| A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%) (NCT03587116) | Pfizer | 2018-07-26 |
| Dose Confirmation Trial of AAV5-hFIXco-Padua (NCT03489291) | CSL Behring | 2018-07-24 |
| A Long-Term Follow-Up Study of Haemophilia B Patients Who Have Undergone Gene Therapy (NCT03641703) | Spur Therapeutics | 2018-07-10 |
| HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients (NCT03569891) | CSL Behring | 2018-06-27 |
| Web Accessible Population Pharmacokinetics Service - Hemophilia: Sources of Variability (NCT03533504) | McMaster University | 2018-05-09 |
| A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors (NCT03417245) | Genzyme, a Sanofi Company | 2018-03-01 |
| A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors (NCT03417102) | Genzyme, a Sanofi Company | 2018-02-14 |
| World Bleeding Disorders Registry (NCT03327779) | World Federation of Hemophilia | 2018-01-26 |
| A Factor IX Gene Therapy Study (FIX-GT) (NCT03369444) | University College, London | 2017-12-05 |
| Joint Health Study (NCT03358836) | Bloodworks | 2017-11-15 |
| Understanding Hemophilia A and B Drug Dosage Administration Patterns (NCT03248141) | Pfizer | 2017-09-01 |
| Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B (NCT03307980) | Pfizer | 2017-06-22 |
| Global Epidemiologic Study of Preexisting Immunity to AAV in Adults With Severe Hemophilia (NCT03185897) | Baxalta now part of Shire | 2017-06-14 |
| Dose-escalation Study to Investigate the Safety, PK, and PD of ISU304/CB2679d in Hemophilia B Patients (NCT03186677) | ISU Abxis Co., Ltd. | 2017-06-03 |
| Data Registry in Chinese Hemophilia A and B Patients (NCT07101224) | Institute of Hematology & Blood Diseases Hospital, China | 2017-05-07 |
| Non-Interventional Study to Capture the Patient Experience on Gene Therapy for Hemophilia Within the AskBio009-101 Study Through Patient and Investigator Interviews (NCT03054389) | Baxalta now part of Shire | 2017-03-31 |
| Post-Marketing Surveillance (Usage Results Study) of RIXUBIS in Adult and Pediatric Patients With Haemophilia B in South Korea (NCT02922231) | Baxalta now part of Shire | 2017-01-06 |
| Long-Term Safety, Tolerability, and Efficacy of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B (NCT02971969) | Ultragenyx Pharmaceutical Inc | 2017-01-01 |
| German Pediatric Hemophilia Research Database (NCT02912143) | Goethe University | 2017-01-01 |
| UK - EHL Outcomes Registry (NCT02938156) | Royal Free Hospital NHS Foundation Trust | 2016-12-17 |
| RIXUBIS Drug Use-Result Survey (Japan) (NCT02937831) | Baxalta now part of Shire | 2016-11-16 |
| Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B (NCT02695160) | Sangamo Therapeutics | 2016-11-15 |
| The Hemophilia Ultrasound Project (NCT02807753) | University of Miami | 2016-09-16 |
| Virtual Reality for Hemophilia (NCT03507582) | Nationwide Children's Hospital | 2016-04-01 |
| Treatment Patterns And Outcomes In Patients Treated With Benefix Or Refacto/Refacto AF - A Swedish Cohort Study (NCT02740413) | Pfizer | 2016-01-11 |
| Ultrasonography in Hemophilic Joint Disease and Serum Markers (NCT02634918) | Northwell Health | 2016-01-01 |
| Safety and Dose Finding Study of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B (NCT02618915) | Ultragenyx Pharmaceutical Inc | 2015-12-16 |
| A Gene Therapy Study for Hemophilia B (NCT02484092) | Pfizer | 2015-11-18 |
| A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors (NCT02571569) | Bayer | 2015-10-28 |
| An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B (NCT02554773) | Genzyme, a Sanofi Company | 2015-09-18 |
| Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes (NCT02392156) | Bioverativ Therapeutics Inc. | 2015-07-01 |
| Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia B (NCT02396342) | CSL Behring | 2015-06-10 |
| A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B (NCT02418793) | OPKO Health, Inc. | 2015-05-01 |
| An Open-Label, Single Dose Pharmacokinetic Study of Benefix (Recombinant Factor IX) in Male Chinese Subjects With Hemophilia B (NCT02213250) | Pfizer | 2015-03-01 |
| Safety and Efficacy of Benefix in Patients With Hemophilia B in Usual Care Settings in China (NCT02336178) | Pfizer | 2015-01-01 |
| Web-based Application for the Population Pharmacokinetic Service - Phase 1 (NCT02061072) | McMaster University | 2015-01-01 |
| Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B (NCT02234310) | Bioverativ, a Sanofi company | 2014-11-13 |
| Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBIS (NCT02190149) | Baxalta now part of Shire | 2014-07-22 |
| Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia B (NCT02048111) | Cangene Corporation | 2014-03-01 |
| A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B (NCT02053792) | CSL Behring | 2014-02-06 |
| A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients (NCT02035605) | Sanofi | 2014-01-20 |
| An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With Hemophilia (NCT02199717) | The Hospital for Sick Children | 2013-09-01 |
| Global Hemostatic Methods in Hemophilia and Von Willebrand's Disease (NCT02061033) | Karolinska University Hospital | 2013-03-01 |
| Study on Von Willebrand Disease and Hemophilia in Cuenca, Ecuador (NCT01589848) | Universidad del Azuay | 2013-03-01 |
| Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen (NCT01757405) | Baxalta now part of Shire | 2013-02-20 |
| Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B (NCT01687608) | Baxalta now part of Shire | 2013-02-11 |
| A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B (NCT01662531) | CSL Behring | 2013-01-01 |
| Viscosupplementation in Patients With Hemophilic Arthropathy (NCT01748201) | University of Sao Paulo General Hospital | 2012-11-01 |
| Hemophilia B Gene Therapy With AAV8 Vector (NCT01620801) | Spark Therapeutics, Inc. | 2012-10-01 |
| Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B (NCT01440946) | Bioverativ Therapeutics Inc. | 2012-06-01 |
| A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B (NCT01496274) | CSL Behring | 2012-02-01 |
| BAX 326 Pediatric Study (NCT01488994) | Baxalta now part of Shire | 2011-12-20 |
| BAX 326 Surgery Study in Hemophilia B Patients (NCT01507896) | Baxalta now part of Shire | 2011-12-19 |
| Osteoporosis and MRI Study in Hemophilia (NCT01460147) | Baxalta now part of Shire | 2011-10-30 |
| Study To Compare On-Demand Treatment To A Prophylaxis Regimen Of BeneFIX In Subjects With Moderately Severe to Severe Hemophilia B (NCT01335061) | Pfizer | 2011-09-01 |
| A Safety and Efficacy Study of a Recombinant Factor IX in Patients With Severe Hemophilia B (NCT01361126) | CSL Behring | 2011-07-01 |
| Socialization of Adult Men With Congenital Hemophilia A or B (NCT01510418) | Dana-Farber Cancer Institute | 2011-05-01 |
| BAX 326 (rFIX) Continuation Study (NCT01286779) | Baxalta now part of Shire | 2011-04-12 |
| Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia B (NCT01271868) | Medexus Pharma, Inc. | 2010-11-01 |
| Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein in Subjects With Hemophilia B (NCT01233440) | CSL Behring | 2010-10-01 |
| Comparing the Burden of Illness of Hemophilia in the Developing and the Developed World (NCT01217255) | The Hospital for Sick Children | 2010-09-01 |
| Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B Patients (NCT01174446) | Baxalta now part of Shire | 2010-07-29 |
| IMMUNINE Pre-Treatment Study (NCT01128881) | Baxalta now part of Shire | 2010-05-31 |
| Correlation Between Vitamin D Status and Bone Mineral Density in Patients With Hemophilia (NCT01090206) | Virginia Commonwealth University | 2010-03-01 |
| Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector For Gene Transfer in Hemophilia B (NCT00979238) | St. Jude Children's Research Hospital | 2010-02-22 |
| BeneFIX Drug Use Results Survey [All-Case Surveillance] (NCT01154231) | Pfizer | 2009-10-29 |